Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

25 patients have been included in the study of which 1 has had an early termination an 22 have completed the full study.

A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity

This is an international (Nordic) trial designed to compare the safety and efficacy of active conventional therapy (ACT) and three biologic treatments (Certolizumab-pegol, Abatacept or Tocilizumab) in subjects with early rheumatoid arthritis (RA). The global aim of this study is to assess and compare two alternative de-escalation strategies in patients who achieved low disease activity during first-line therapy in the NORD-STAR study.

Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity

Recruitment

Summary

Participation Requirements

Description

Tracking Information